جهت دسترسی به کاربرگه ی زیر، از این لینک استفاده کنید. http://78.39.227.9/handle/Hannan/52715
Title: Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial
Authors: Zhu, a X;Kudo, M;Assenat, E;Cattan, S;Kang, Y K;Lim, H Y;Poon, R T;Blanc, J F;Vogel, a;Chen, C L;Dorval, E;Peck-Radosavljevic, M;Santoro, a;Daniele, B;Furuse, J;Jappe, a;Perraud, K;Anak, O;Sellami, D B;Chen, L T
Keywords: Adult;Aged;Aged, 80 and over;Antineoplastic Agents/adverse effects/ therapeutic;Carcinoma, Hepatocellular/ drug therapy;Disease Progression;Double-Blind Method;Female;Humans;Liver Neoplasms/ drug therapy;Liver/drug effects/physiopathology;Male
Issue Date: 2014
Abstract: IMPORTANCE: Aside from the multikinase inhibitor sorafenib, there are no effective systemic therapies for the treatment of advanced hepatocellular carcinoma. OBJECTIVE: To assess the efficacy of everolimus in patients with advanced hepatocellular carcinom
URI: http://ebook.muk.ac.ir/handle/Hannan/52715
ISSN: 1538-3598 (Electronic)\n0098-7484 (Linking)
Format: VOLUME : 312
ISSUE : 1
START PAGE : 57
END PAGES : 67
Appears in Collections:2014

Files in This Item:
File Description SizeFormat 
medicine article ap (152).pdf137.74 kBAdobe PDFThumbnail
Download    Request a copy


تمامی کاربرگه ها در کتابخانه ی دیجیتال حنان به صورت کامل محافظت می شوند.